We are live on ! Find out more
MRKR icon

Marker Therapeutics
MRKR

6 hedge funds and large institutions have $163K invested in Marker Therapeutics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

37% more capital invested

Capital invested by funds: $119K → $163K (+$44K)

20% more funds holding

Funds holding: 5 → 6 (+1)

0.05% more ownership

Funds ownership: 0.38% → 0.43% (+0.05%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$53.9K
2
Goldman Sachs
Goldman Sachs
New York
+$47.1K
3
NSIM
North Star Investment Management
Illinois
+$9.92K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$60.4K
2
PAM
Panagora Asset Management
Massachusetts
-$23K

MRKR Hedge Fund Activity: Q1 2017 in Review

6 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2017, worth a combined $163K — up 37% from $119K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new MRKR positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $53.9K. The largest seller was Millennium Management, cutting an estimated $60.4K.

  • 6 institutional investors held Marker Therapeutics (MRKR) as of Q1 2017, up from 5 in Q4 2016.
  • Funds reported $163K of Marker Therapeutics stock for Q1 2017, up 37% quarter-over-quarter.
  • 3 funds opened new Marker Therapeutics positions in Q1 2017 and 2 closed out, a net change of +1 holder.
  • The largest Marker Therapeutics buyer in Q1 2017 was Virtu KCG Holdings, an estimated $53.9K added.
  • The largest Marker Therapeutics seller in Q1 2017 was Millennium Management, an estimated $60.4K sold.

Based on aggregated 13F filings for Q1 2017.